|
WORKPACKAGES
4.3. Deliverables
- D.1 Consortium Agreement.
- WP no.7 | Lead participant: 1 | Est. person-months: 0.7 | Nature: O | Dissemination level: PP | Delivery date: 2
- D.2 Final plan for using and disseminating knowledge
- WP no.7 | Lead participant: 1 | Est. person-months: 0.46 | Nature: R | Dissemination level: PU | Delivery date: 2
- D.3 Report on raising public participation and awareness
- WP no.7 | Lead participant: 1 | Est. person-months: 0.32 | Nature: R | Dissemination level: PU | Delivery date: 2
- D.4 Project presentation: Development of project website
- WP no.7 | Lead participant: 1 | Est. person-months: 0.52 | Nature: O | Dissemination level: PU/PP | Delivery date: 2
- D.5 Knowledge about the production of cytokines by FMDV infected porcine cells
- WP no.3 | Lead participant: 3 | Est. person-months: 3.5 | Nature: O | Dissemination level: PU | Delivery date: 12
- D.6 Project Management Team meeting, project meeting and report, year 1
- WP no.7 | Lead participant: 1 | Est. person-months: 5.45 | Nature: O | Dissemination level: PU | Delivery date: 16
- D.7 NSP standard reference sera and an inter-laboratory serum panels for proficiency tests
- WP no.1 | Lead participant: 2 | Est. person-months: 9 | Nature: O | Dissemination level: PP | Delivery date: 18
- D.8 Peptides representing immunogenic regions of NSPs
- WP no.2 | Lead participant: 7 | Est. person-months: 7 | Nature: O | Dissemination level: RE | Delivery date: 18
- D.9 Characteristics of dendritic cell targeting by conventional FMDV vaccine serotype O
- WP no.6 | Lead participant: 10 | Est. person-months: 32 | Nature: O | Dissemination level: PU | Delivery date: 18
- D.10 New indirect NSP-peptide ELISA (prototype)
- WP no.2 | Lead participant: 7 | Est. person-months: 7 | Nature: O | Dissemination level: RE | Delivery date: 24
- D.11 ELISAs (indirect or competitive) using serotype specific VP1s
- WP no.2 | Lead participant: 9 | Est. person-months: 7 | Nature O | Dissemination level: PU | Delivery date: 24
- D.12 Knowledge to prevent reduction of infection by interferon producing cells and therefore improvement of VI on cell cultures
- WP no.3 | Lead participant: 3 | Est. person-months: 6 | Nature: O | Dissemination level: PU | Delivery date: 24
- D.13 Project Management Team meeting, project meeting and report, year 2
- WP no.7 | Lead participant: 1 | Est. person-months: 5.3 | Nature: O | Dissemination level: PU | Delivery date: 28
- D.14 Better knowledge of the impact of vaccination on virus circulation and improved sampling strategies
- WP no.1 | Lead participant: 4 | Est. person-months: 12.5 | Nature: O | Dissemination level: PU | Delivery date: 36
- D.15 Multispecies competition-based NSP-ELISAs (prototype)
- WP no.2 | Lead participant: 7 | Est. person-months: 12.5 | Nature: O | Dissemination level: PU | Delivery date: 36
- D.16 3D ELISAs for serotype-independent antibody detection
- WP no.2 | Lead participant: 9 | Est. person-months: 17.5 | Nature: O | Dissemination level: PU | Delivery date: 36
- D.17 Developed and validated RCA-ELISA
- WP no.3 | Lead participant: 1 | Est. person-months: 25 | Nature: O | Dissemination level: PU | Delivery date: 36
- D.18 Developed and validated IgA-ELISA and determined correlation of IgA between infection and carrier state in vaccinated cattle
- WP no.3 | Lead participant: 5 | Est. person-months: 6.5 | Nature: O | Dissemination level: PU | Delivery date: 36
- D.19 Characterised potential of marker vaccines to target dendritic cells
- WP no.6 | Lead participant: 10 | Est. person-months: 10 | Nature: O | Dissemination level: PU | Delivery date: 36
- D.20 Dendritic cell characteristics associated with the FMDV vaccines targeting these cells
- WP no.6 | Lead participant: 10 | Est. person-months: 17 | Nature: O | Dissemination level: PU | Delivery date: 36
- D.21 Proposal of vaccine candidates with potential to promote mucosal immunity
- WP no.6 | Lead participant: 10 | Est. person-months: 7.1 | Nature: RE | Dissemination level: PU | Delivery date: 36
- D.22 Project Management Team meeting, project meeting and report, year 3
- WP no.7 | Lead participant: 1 | Est. person-months: 5.4 | Nature: O | Dissemination level: PU | Delivery date: 40
- D.23 Validated NSP-ELISAs to discriminate infected from vaccinated animals
- WP no.1 | Lead participant: 3 | Est. person-months: 17.5 | Nature: O | Dissemination level: PU | Delivery date: 42
- D.24 Improved NSP-tests and control strategy
- WP no.1 | Lead participant: 7 | Est. person-months: 17 | Nature: O | Dissemination level: PU | Delivery date: 42
- D.25 An enzymatic NSP-assay based on engineered E.coli b-galactosidase enzymatic sensor displaying immuno-dominant NSP-epitopes of FMDV
- WP no.2 | Lead participant: 6 | Est. person-months: 50 | Nature: O | Dissemination level: PP | Delivery date: 48
- D.26 Positive and negative discrimination of the polyclonal antibody response against the chimeric and natural virus response
- WP no.2 | Lead participant: 2 | Est. person-months: 3 | Nature: O | Dissemination level: PP | Delivery date: 48
- D.27 Validated new and confirmatory NSP assays
- WP no.2 | Lead participant: 4 | Est. person-months: 34.5 | Nature: O | Dissemination level: RE | Delivery date: 48
- D.28 ELISAs using FMD-VLP and comparison to former VP1 ELISAs
- WP no.2 | Lead participant: 9 | Est. person-months: 12 | Nature: O | Dissemination level: PU | Delivery date: 48
- D.29 Comparative tool for validation of NSP-tests without gold standard
- WP no.3 | Lead participant: 1 | Est. person-months: 11 | Nature: O | Dissemination level: PU | Delivery date: 48
- D.30 Knowledge on the clinical protective effect of FMD vaccination against contact challenge in cattle, calves, sheep and pigs and on how varying dose of vaccine and vaccine/challenge intervals affect this
- WP no.4 | Lead participant: 2 | Est. person-months: 30 | Nature: O | Dissemination level: PU | Delivery date: 48
- D.31 Knowledge on the effect of FMD vaccination in preventing virus replication and shedding in contact challenged cattle, calves, sheep and pigs and on how varying dose of vaccine and vaccine/challenge intervals affect this
- WP no.4 | Lead participant: 3 | Est. person-months: 13 | Nature: O | Dissemination level: PU | Delivery date: 48
- D.32 Knowledge on the effect of high potency vaccination in reducing the development of the carrier state in cattle
- WP no.4 | Lead participant: 2 | Est. person-months: 24 | Nature: O | Dissemination level: PU | Delivery date: 48
- D.33 Estimation of the reproduction ratio in vaccinated calves, cows, sheep and pigs
- WP no.4 | Lead participant: 3 | Est. person-months: 4 | Nature: O | Dissemination level: PU | Delivery date: 48
- D.34 Sera and other clinical materials from vaccinated/unvaccinated and contact challenged cattle, calves, sheep and pigs for the development and validation of tests to detect infection, regardless of vaccination status
- WP no.4 | Lead participant: 2 | Est. person-months: 19 | Nature: O | Dissemination level: PP | Delivery date: 48
- D.35 Improved r-value
- WP no.5 | Lead participant: 1 | Est. person-months: 26.5 | Nature: O | Dissemination level: PU | Delivery date: 48
- D.36 Data on relation of antigen profiling and protection against heterological challenge
- WP no.5 | Lead participant: 7 | Est. person-months: 16 | Nature: O | Dissemination level: PU | Delivery date: 48
- D.37 Data on relation of genotyping and protection against heterological challenge
- WP no.5 | Lead participant: 2 | Est. person-months: 9.5 | Nature: O | Dissemination level: PU | Delivery date: 48
- D.38 Samples for all assay validation and development during this project
- WP no.5,6 | Lead participant: 5,2 | Est. person-months: 36 | Nature: O | Dissemination level: PP | Delivery date: 48
- D.39 Characterised MAbs panels suited for antigen profiling and improved antigen profiling
- WP no.5 | Lead participant: 7 | Est. person-months: 21 | Nature: O | Dissemination level: CO | Delivery date: 48
- D.40 Improved sequencing for detecting and identifying FMDV genetic variants with different response to vaccines
- WP no.5 | Lead participant: 4 | Est. person-months: 27 | Nature: O | Dissemination level: PU | Delivery date: 48
- D.41 Alternative potency test
- WP no.5 | Lead participant: 8 | Est. person-months: 21 | Nature: O | Dissemination level: PU | Delivery date: 48
- D.42 Better knowledge of FMDV strain selection in endemic areas of the world and data on the ability to adapt antigen of vaccines to specific epidemiological situations
- WP no.5 | Lead participant: 4 | Est. person-months: 36.5 | Nature: O | Dissemination level: PU | Delivery date: 48
- D.43 A chimera marker FMDV A12-O1 vaccine
- WP no.6 | Lead participant: 2 | Est. person-months: 7 | Nature: O | Dissemination level: RE | Delivery date: 48
- D.44 A chimera marker FMDV A12-C3 vaccine
- WP no.6 | Lead participant: 2 | Est. person-months: 7 | Nature: O | Dissemination level: RE | Delivery date: 48
- D.45 A chimera marker FMDV A12-'foreign' RGD vaccine
- WP no.6 | Lead participant: 2 | Est. person-months: 7 | Nature: O | Dissemination level: RE | Delivery date: 48
- D.46 The antigenic spectrum of these chimera marker vaccines
- WP no.6 | Lead participant: 2 | Est. person-months: 7 | Nature: O | Dissemination level: RE | Delivery date: 48
- D.47 Potency (PD50) value of the different chimera marker vaccines
- WP no.6 | Lead participant: 2 | Est. person-months: 7 | Nature: O | Dissemination level: RE | Delivery date: 48
- D.48 Potency by serology of the different chimera marker vaccines
- WP no.6 | Lead participant: 2 | Est. person-months: 7 | Nature: O | Dissemination level: RE | Delivery date: 48
- D.49 Potency of dendritic cell targeting of vaccine at promoting mucosal immunity and protection against FMDV
- WP no.6 | Lead participant: 10 | Est. person-months: 18.5 | Nature: O | Dissemination level: RE | Delivery date: 48
- D.50 Reports/Scientific publications
- WP no.1,2,3,4,5 & 6 | Lead participant: 1 | Est. person-months: 27.4 | Nature: R | Dissemination level: PP/PU | Delivery date: 48
- D.51 Project Management Team meeting, project meeting and report and final report, year 4
- WP no.7 | Lead participant: 1 | Est. person-months: 6.35 | Nature: O | Dissemination level: PU | Delivery date: 48
Total Person-months: 720,5
|
|